Cymabay Therapeu Valuation
| CBAYDelisted Stock | USD 11.83 0.27 2.34% |
At this time, the firm appears to be overvalued. Cymabay Therapeu shows a prevailing Real Value of $9.13 per share. The current price of the firm is $11.83. Our model approximates the value of Cymabay Therapeu from analyzing the firm fundamentals such as Shares Outstanding of 114.78 M, operating margin of (745.58) %, and Return On Equity of -0.64 as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Cymabay Therapeu's price fluctuation is very steady at this time. Calculation of the real value of Cymabay Therapeu is based on 3 months time horizon. Increasing Cymabay Therapeu's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Cymabay Therapeu is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Cymabay Stock. However, Cymabay Therapeu's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 11.83 | Real 9.13 | Hype 11.83 | Naive 11.17 |
The intrinsic value of Cymabay Therapeu's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Cymabay Therapeu's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Cymabay Therapeu helps investors to forecast how Cymabay stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Cymabay Therapeu more accurately as focusing exclusively on Cymabay Therapeu's fundamentals will not take into account other important factors: Cymabay Therapeu Total Value Analysis
Cymabay Therapeu is currently forecasted to have valuation of 3.45 B with market capitalization of 3.73 B, debt of 114.49 M, and cash on hands of 153.42 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Cymabay Therapeu fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
3.45 B | 3.73 B | 114.49 M | 153.42 M |
Cymabay Therapeu Investor Information
About 99.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 0.99. Cymabay Therapeu had not issued any dividends in recent years. Based on the key indicators related to Cymabay Therapeu's liquidity, profitability, solvency, and operating efficiency, Cymabay Therapeu is not in a good financial situation at the moment. It has a very high risk of going through financial straits in January.Cymabay Therapeu Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Cymabay Therapeu has an asset utilization ratio of 7.15 percent. This suggests that the Company is making $0.0715 for each dollar of assets. An increasing asset utilization means that Cymabay Therapeu is more efficient with each dollar of assets it utilizes for everyday operations.Cymabay Therapeu Ownership Allocation
The majority of Cymabay Therapeu outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Cymabay Therapeu to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Cymabay Therapeu. Please pay attention to any change in the institutional holdings of Cymabay Therapeu as this could imply that something significant has changed or is about to change at the company.Cymabay Therapeu Profitability Analysis
The company reported the previous year's revenue of 31.07 M. Net Loss for the year was (105.37 M) with loss before overhead, payroll, taxes, and interest of (41.63 M).About Cymabay Therapeu Valuation
Our relative valuation model uses a comparative analysis of Cymabay Therapeu. We calculate exposure to Cymabay Therapeu's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Cymabay Therapeu's related companies.CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California. Cymabay Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 59 people.
Cymabay Therapeu Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 106.2 M |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in Cymabay Stock
If you are still planning to invest in Cymabay Therapeu check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Cymabay Therapeu's history and understand the potential risks before investing.
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity |